COTA has announced a partnership with precision oncology pioneer Guardant Health

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

This collaboration will provide biopharmaceutical researchers with access to COTA’s research-grade electronic health record (EHR) data from academic and community care centers, combined with Guardant’s clinicogenomic testing data, to accelerate the development of innovative cancer therapies.

“Clinicogenomic data empowers research scientists to test hypotheses by studying patient genomic profiles and real-world outcomes to guide the development of targeted therapies that can be used to personalize treatment for each cancer patient.

Connecting Guardant’s data to COTA’s in-depth, real-world oncology data assets will also allow researchers to anticipate treatment responses and accelerate drug development for existing and new population segments.” – said Dr. C.K. Wang, chief medical officer at COTA.

Leveraging a robust dataset and advanced AI analytics, this partnership will enable researchers to better understand and validate the connections between molecular biomarkers, treatment decisions, and clinical outcomes.

It will also enhance the ability to generate and analyze comprehensive data—including critical longitudinal serial testing information—essential for optimizing drug development and advancing cancer treatments for diverse patient populations.

“The real-world data partnership with COTA marks another milestone in our mission to conquer cancer with data.

Giving biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data will expedite the discovery of new biomarker-based therapies for patients and make the drug development process more economical as well.” – said Craig Eagle, MD, Guardant Health chief medical officer.

The traditional drug development process is lengthy and challenging, with approximately 97% of cancer clinical trials failing and timelines often stretching to 15 years.

Recognizing this, life sciences organizations are increasingly investing in multi-modal datasets like clinicogenomics.

These datasets provide critical insights into how various patient populations respond to therapies in real-world settings, facilitating biomarker discovery, refining clinical trials, and accelerating the approval and delivery of targeted treatments to market.

Guardant’s extensive datasets include longitudinal serial testing across all stages of disease – from initial tumor profiling for therapy selection to monitoring recurrence and therapy response.

COTA’s curated data tracks comprehensive cancer care journeys from academic and community settings. By combining their resources, the collaboration significantly enhances the breadth and depth of available data, particularly for solid tumors like lung, breast, and colorectal cancers, enabling deeper clinical insights through greater patient overlap.

About COTA

Founded by oncologists, COTA focuses on delivering precise, patient-centered cancer care using real-world data. Through technology-supported data abstraction methods, COTA organizes complex patient information into actionable insights.

Partnering with life sciences companies, providers, and payers, COTA’s high-quality oncology data and advanced analytics platform aim to improve cancer care and outcomes.

About Guardant Health 

Guardant Health, established in 2012, is a leading precision oncology company dedicated to transforming cancer care. Through its advanced blood and tissue tests, real-world data, and AI-driven analytics, Guardant provides critical insights to improve patient outcomes across all stages of cancer—from early detection and recurrence monitoring to therapy selection.